Evolus (NASDAQ:EOLS) Reaches New 12-Month Low – Should You Sell?

Evolus, Inc. (NASDAQ:EOLS)’s stock price hit a new 52-week low on Tuesday . The stock traded as low as $9.48 and last traded at $9.80, with a volume of 917290 shares changing hands. The stock had previously closed at $10.00.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, November 7th.

Evolus Stock Performance

The firm has a fifty day simple moving average of $12.24 and a 200 day simple moving average of $13.76. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $620.55 million, a price-to-earnings ratio of -10.77 and a beta of 1.32.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of EOLS. Caligan Partners LP increased its holdings in Evolus by 1.2% in the 3rd quarter. Caligan Partners LP now owns 2,193,488 shares of the company’s stock valued at $35,535,000 after buying an additional 25,698 shares during the period. Geode Capital Management LLC raised its position in Evolus by 0.9% in the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock worth $19,616,000 after purchasing an additional 11,027 shares in the last quarter. Lord Abbett & CO. LLC lifted its stake in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after purchasing an additional 188,685 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Evolus by 0.9% during the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company’s stock valued at $15,480,000 after purchasing an additional 8,452 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in shares of Evolus by 6.3% in the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock valued at $14,659,000 after purchasing an additional 53,605 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.